A small case series of nine patients showed that the use of anti‐CGRP mAbs for migraine in people with relapsing–remitting MS was associated with AEs in 33% of the cases, with two patients experiencing, respectively, a progression in the Expanded Disability Status Scale score and a new radiological relapse [7]. The gene discussed is CALCA; the disease is migraine disorder.